Incyte Corporation vs Zillow Group Inc Class A — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Incyte Corporation is far larger — about 3.5× Zillow Group Inc Class A's market cap, and Incyte Corporation is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Zillow Group Inc Class A for 86 Days on average.
| INCY | ZG | |
|---|---|---|
Market Cap | $22.85B | $6.59B |
Volume | 1,927,029 | 1,361,381 |
Sector | Health | Media |
52-Week High | $129.93 | $74.58 |
52-Week Low | $83.80 | $27.70 |
Typical Hold Time | 33 Days | 86 Days |
Enterprise Value | $18.35B | $6.47B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Zillow Group (ZG) trades at $29.87, up 6.79% on the day, showing strong momentum despite mixed technical signals. The company has demonstrated improved financial performance with revenue growth from $2.2B in 2024 to $2.6B in 2025 and achieving profitability with $23M net income after three years of losses. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though Q4 2025 missed expectations. Analyst consensus remains divided with a Hold rating but offers significant upside potential with a $48.87 price target.
The outlook for ZG appears cautiously optimistic with fundamental improvement offset by housing market headwinds. Investment opportunity lies in the company's transition to profitability and market share gains in digital real estate, while risks include interest rate sensitivity, competitive pressures from Compass, and ongoing housing affordability challenges that could impact transaction volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →